EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

The 2024 diagnostic criteria for primary sclerosing cholangitis

Itaru Naitoh, Hiroyuki Isayama iD, Nobuhisa Akamatsu, Suguru Mizuno, Toshio Fujisawa, Nobuhiro Nakamoto, Yousuke Nakai, Shuichiro Umetsu, Mitsuyoshi Suzuki, Shintaro Yagi, Hironori Haga, Kenji Notohara und 4 weitere

Journal of Gastroenterology · 2025-10 · 60 (10) · 1221-1231

DOI: 10.1007/s00535-025-02265-5 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Gastroenterology, online erschienen am 12.06.2025. Verfasst von Itaru Naitoh und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Nagoya City University Midori Municipal Hospital, Nagoya, Japan. Hauptthemen laut MEDLINE: Cholangitis, Sclerosing. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Intractable Diseases Research Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Primary sclerosing cholangitis (PSC) is an idiopathic chronic cholestatic disease with a poor prognosis. As there were no specific biomarkers for diagnosing PSC, we developed diagnostic criteria in 2016 based on cholangiography and elevated biliary enzymes. Novel findings and knowledge have subsequently accumulated, and we now propose the 2024 diagnostic criteria, to overcome several limitations of the 2016 diagnostic criteria. The Intractable Hepato-Biliary Diseases Study Group in Japan of the Committee of Research on Measures for Intractable Diseases established a working group consisting of experts in PSC comprising gastroenterologists, endoscopists, hepatologists, liver-transplant surgeons, pediatric hepatologists, pathologists, and radiologists. This working group proposed the 2024 diagnostic criteria after several discussions and public hearings. There are additional diagnostic targets; small duct PSC, pediatric PSC, and PSC recurrence following liver transplantation differ from the 2016 diagnostic criteria, which were for diagnosing large duct PSC in adults. The 2024 diagnostic criteria facilitate the use of magnetic resonance cholangiography in addition to endoscopic retrograde cholangiography in imaging, and incorporate gamma-glutamyl transferase for evaluating cholestasis to diagnose pediatric patients. Furthermore, PSC recurrence following liver transplantation can be diagnosed based on a liver biopsy and characteristic biliary findings. We hope that the 2024 diagnostic criteria will help not only hepatologists treating adults but also general physicians, pediatric hepatologists, and liver-transplant surgeons who manage patients with various forms of PSC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cholangitis, SclerosingHumansLiver TransplantationCholangiographyChildgamma-GlutamyltransferaseJapanCholangiopancreatography, Endoscopic RetrogradeRecurrenceAdultCholangiopancreatography, Magnetic Resonance

Stichwörter der Autor:innen

Diagnostic criteriaLarge duct primary sclerosing cholangitisPrimary sclerosing cholangitisRecurrence following liver transplantationSmall duct primary sclerosing cholangitis

Substanzen

gamma-Glutamyltransferase

Autor:innen und Institutionen

  • Department of Gastroenterology, Nagoya City University Midori Municipal Hospital, Nagoya, Japan.
  • Department of Gastroenterology, Graduate School of Medicine, Juntendo University, 2-1-1 Hongo, Bunkyo City, Tokyo, 113-8421, Japan. h-isayama@juntendo.ac.jp.
  • Artificial Organ and Transplantation Surgery Division, Department of Surgery, Graduate School of Medicine, University of Tokyo, Tokyo, Japan.
  • Department of Gastroenterology and Hepatology, Faculty of Medicine, Saitama Medical University, Saitama, Japan.
  • Department of Gastroenterology, Graduate School of Medicine, Juntendo University, 2-1-1 Hongo, Bunkyo City, Tokyo, 113-8421, Japan.
  • Division of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan.

ORCID-Profile: Hiroyuki Isayama

Förderung

  • Japan Intractable Diseases Research Foundation

Zitieren

APA

Naitoh, I., Isayama, H., Akamatsu, N., Mizuno, S., Fujisawa, T., Nakamoto, N., Nakai, Y., Umetsu, S., Suzuki, M., Yagi, S., Haga, H., Notohara, K., Sano, K., Tazuma, S., Nakazawa, T., & Tanaka, A. (2025). The 2024 diagnostic criteria for primary sclerosing cholangitis. Journal of Gastroenterology, 60(10), 1221-1231. https://doi.org/10.1007/s00535-025-02265-5

Vancouver

Naitoh I, Isayama H, Akamatsu N, Mizuno S, Fujisawa T, Nakamoto N, et al. The 2024 diagnostic criteria for primary sclerosing cholangitis. Journal of Gastroenterology. 2025;60(10):1221-1231. doi:10.1007/s00535-025-02265-5

BibTeX
@article{Naitoh2025,
  author = {Naitoh, Itaru and Isayama, Hiroyuki and Akamatsu, Nobuhisa and Mizuno, Suguru and Fujisawa, Toshio and Nakamoto, Nobuhiro and Nakai, Yousuke and Umetsu, Shuichiro and Suzuki, Mitsuyoshi and Yagi, Shintaro and Haga, Hironori and Notohara, Kenji and Sano, Katsuhiro and Tazuma, Susumu and Nakazawa, Takahiro and Tanaka, Atsushi},
  title = {The 2024 diagnostic criteria for primary sclerosing cholangitis},
  journal = {Journal of Gastroenterology},
  year = {2025},
  volume = {60},
  number = {10},
  pages = {1221--1231},
  doi = {10.1007/s00535-025-02265-5}
}
Kostenlos starten →